Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder

INTRODUCTION: Economic impact data for anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) are generally limited to direct medical patient costs and exclude indirect, nonmedical, and uncovered healthcare patient and caregiver costs. Here, we estimated the total economic impact of AQP4-Ab+ NMOSD in 2024 on US patients and caregivers. METHODS: This study consisted of two portions: an independent, electronically administered survey to capture indirect, nonmedical, and uncovered healthcare costs of AQP4-Ab+ NMOSD from 2023 to patients and caregivers (adjusted for inflation to 2024 dollars); and a retrospective, matched cohort claims analysis to estimate excess direct medical costs of AQP4-Ab+ NMOSD in 2024 to patients. Adults living in the USA or its territories were eligible. Annual costs for patients were calculated as the sum of weighted average indirect, nonmedical, uncovered healthcare, and excess direct costs, multiplied by the US prevalence of AQP4-Ab+ NMOSD. Annual cost for caregivers was calculated as the sum of unweighted average indirect, nonmedical, and uncovered healthcare costs, multiplied by the estimated prevalence of patients with AQP4-Ab+ NMOSD with a caregiver. RESULTS: Of 258 respondents, 209 were patients (female, 76%; mean ± SD age, 45.1 ± 12.6 years; 44% reported a relapse in 2023; 53% had an informal caregiver) and 49 were caregivers (female, 57%; mean ± SD age, 42.1 ± 13.6 years). Estimated total economic impact of AQP4-Ab+ NMOSD in 2024 dollars was $1.06 billion (excess direct medical costs, $574.2 million [54%]; patient indirect, nonmedical, and uncovered healthcare costs, $315.3 million [30%]; caregiver indirect, nonmedical, and uncovered healthcare costs, $171.5 million [16%]). Average annual indirect, nonmedical, and uncovered healthcare costs were $51,513/patient and $54,036/caregiver. CONCLUSION: Indirect, nonmedical, and uncovered healthcare costs comprise approximately half the total economic impact of AQP4-Ab+ NMOSD. These results show the importance of treating patients with optimal therapies to reduce the burden on patients and caregivers. Graphical Abstract is available with this article.

Authors

Institutions

Publication Details

Journal
Neurology and Therapy
Published
2026-11-12
DOI
https://doi.org/10.1007/s40120-026-01053-4
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder

Caitlin N. Dodd, Asger Hegelund Olsen, Mayvis Rebeira, Benjamin Osborne et al.
Neurology and Therapy
Multiple Sclerosis Research Studies
article

Total Economic Impact of Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder

Caitlin N. Dodd, Asger Hegelund Olsen, Mayvis Rebeira, Benjamin Osborne, Evanthia Bernitsas, Alexis C. Garduno, Nicole Betor, Jeffrey C. Yu, Jamie B. Sullivan, Lindsey M. Przybyl, Jesus Loreto, Justin Lee
article en

Abstract

INTRODUCTION: Economic impact data for anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) are generally limited to direct medical patient costs and exclude indirect, nonmedical, and uncovered healthcare patient and caregiver costs. Here, we estimated the total economic impact of AQP4-Ab+ NMOSD in 2024 on US patients and caregivers. METHODS: This study consisted of two portions: an independent, electronically administered survey to capture indirect, nonmedical, and uncovered healthcare costs of AQP4-Ab+ NMOSD from 2023 to patients and caregivers (adjusted for inflation to 2024 dollars); and a retrospective, matched cohort claims analysis to estimate excess direct medical costs of AQP4-Ab+ NMOSD in 2024 to patients. Adults living in the USA or its territories were eligible. Annual costs for patients were calculated as the sum of weighted average indirect, nonmedical, uncovered healthcare, and excess direct costs, multiplied by the US prevalence of AQP4-Ab+ NMOSD. Annual cost for caregivers was calculated as the sum of unweighted average indirect, nonmedical, and uncovered healthcare costs, multiplied by the estimated prevalence of patients with AQP4-Ab+ NMOSD with a caregiver. RESULTS: Of 258 respondents, 209 were patients (female, 76%; mean ± SD age, 45.1 ± 12.6 years; 44% reported a relapse in 2023; 53% had an informal caregiver) and 49 were caregivers (female, 57%; mean ± SD age, 42.1 ± 13.6 years). Estimated total economic impact of AQP4-Ab+ NMOSD in 2024 dollars was $1.06 billion (excess direct medical costs, $574.2 million [54%]; patient indirect, nonmedical, and uncovered healthcare costs, $315.3 million [30%]; caregiver indirect, nonmedical, and uncovered healthcare costs, $171.5 million [16%]). Average annual indirect, nonmedical, and uncovered healthcare costs were $51,513/patient and $54,036/caregiver. CONCLUSION: Indirect, nonmedical, and uncovered healthcare costs comprise approximately half the total economic impact of AQP4-Ab+ NMOSD. These results show the importance of treating patients with optimal therapies to reduce the burden on patients and caregivers. Graphical Abstract is available with this article.

Neurology and Therapy
Creighton University (US), Georgetown University Medical Center (US), MedStar Georgetown University Hospital (US), Alexion Pharmaceuticals (United States) (US), AstraZeneca (Canada) (CA)
AstraZeneca, Alexion Pharmaceuticals, University of Toronto
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon